You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
GenMark said it placed 70 net ePlex analyzers in Q3 and ended the quarter with a global installed base of more than 720 ePlex analyzers.
The company's CEO said that its single-molecule tethering technology has demonstrated limits of detection comparable to commercial molecular tests.
The new method incorporates analysis of the amplification and melt curves and was used to create a single-channel nonaplex test using intercalating dye.
Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.
Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.
The firm said its ELISA multiplex SARS-CoV-2 test may enable early diagnosis of infected patients and broaden the number of testing options at the point of care.
The firm launched a CE-IVD marked test for extremely drug-resistant TB and expects to incorporate the multiplexing technology in other assays.
A research team said the study provides some evidence that there is potential for saliva testing in broad surveillance of past exposure to SARS-CoV-2.
A Korean research team is developing a biosensor that boosted sensitivity by using low-cost fabrication to align high-density carbon nanotubes.
The firm said that its Verigene II multiplex system is on track to launch in mid-2020 among a number of new products scheduled for release this year.